We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » NICE responds to article in The Times

NICE responds to article in The Times

September 4, 2013
CenterWatch Staff

The National Institute for Health and Care Excellence (NICE) has called on pharmaceutical companies to question the development costs of new medicines.

In a letter to The Times, Sir Andrew Dillon, chief executive of NICE, acknowledged the expense of bringing new drugs to market, but said health services had to be confident that the extra benefits for patients justified the price.

Dillon was responding to a comment piece by the business editor at The Times, Ian King, who argued the NICE's decisions could influence the decisions of drug companies to locate in the U.K.

Sir Andrew's letter reads:

Sir,

Ian King (Business Commentary, 30 August) says that unless NICE stops restricting access to drugs because they are too expensive or they have too many harmful side effects for patients, the pharmaceutical industry will stop developing drugs in the U.K.

I suspect that the research and clinical environment here holds too many advantages for companies to do that, though it is certainly the case that there is a global market for life sciences R&D and the U.K. has to compete hard to win its share.

Mr. King quotes Jonathan Emms, the managing director of Pfizer in the U.K., who says that it costs £1.2 billion ($1.58 billion) to bring a new medicine to patients. Although this is a number that seems to go up each time it's estimated, it clearly is expensive to develop new drugs.

Companies are entitled to expect a return on their investment, but health services have to be confident that the extra benefit to patients justifies the price. It mostly does so, though sometimes at a stretch. If we are not sure, we have to say so, in the interests of all those of us who expect the NHS to apply its resources equitably across all of the demands we make of it.

NICE is, quite properly, scrutinized closely on its decisions and the methods we use to arrive at them. We have changed and improved over the decade and more that we have been advising the NHS. We are not perfect, but we are respected throughout the world for the quality of our work.

If it really does cost £1.2 billion ($1.58 billion) to develop a new drug, the question the pharmaceutical industry must be able to answer is this: are you absolutely confident that it needs to?

Andrew Dillon

Chief Executive

National Institute for Health and Care Excellence

Upcoming Events

  • 09Dec

    The Age of eSource: Modernizing Clinical Trials

  • 16Dec

    Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

Featured Products

  • Regenerative-medicine-steps-to-accelerate-development-pdf

    Regenerative Medicine: Steps to Accelerate Development — PDF

  • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

    Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

Featured Stories

  • Patient-phsyician-consultation

    Giving Patients Back Their Voice in Clinical Trials

  • Ich_logo

    ICH Overhauls 22-Year-Old Clinical Studies Guideline

  • Survey_chart2019

    Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

New!

2019 Site Survey Reports

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing